Power Mall warning letter
This article was originally published in The Tan Sheet
Executive SummaryFDA cites claims that Power Mall's Q Gel dietary supplement can "provide effective treatment of heart disease, chronic fatigue and support during cancer treatment" in a recent warning letter to the company. A review of the firm's website also finds that Gastro Enzymes claims to treat "ulcers, colitis, duodenal ulcer, gastritis, unexplained blood in urine..." the agency adds. Other products cited in the letter for making drug claims include Taurine Spray, AsmaSpray,D-Lenolate,Curcumin98,OxySorb, Eskimo 3 Fish Oil and AtaXanthin. FDA allows Power Mall 15 working days to notify the agency of the steps it is taking to correct the violations...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.